We explored the potential of melatonin as a treatment for H1N1 flu infection. In our study, we found that melatonin, a powerful antioxidant and anti-inflammatory compound, could significantly protect against the flu in both laboratory tests and in living mice.
Our findings showed that higher local levels of melatonin in the nose and lungs correlated with lower death rates from the virus. In fact, melatonin-deficient mice had much higher mortality rates, which were notably reduced when treated with melatonin.
We discovered that melatonin primarily works by targeting mast cells, which are important players in the body’s immune response. By suppressing the activation of these cells after H1N1 infection, melatonin helps control the release of inflammatory proteins, leading to less damage in lung tissue. This mechanism highlights how melatonin treatment can prevent serious lung injury caused by the virus, opening up new avenues for post-flu recovery strategies.
Read More
Melatonin's limited effect on flu immunityA randomized clinical trial of the impact of melatonin on influenza vaccine: Outcomes from the melatonin and vaccine response immunity and chronobiology study (MAVRICS).
Study shows mixed results
We conducted a randomized open-label trial to explore how melatonin might influence our immune response to the flu vaccine. Our team grouped adults who were set to receive the flu shot into two categories: one that received 5 mg of melatonin and another that served as the control group. We assessed their immune responses through various tests two to three weeks after getting vaccinated.
With a total of 108 participants involved, our baseline assessment—which included sleep quality—showed similar characteristics across both groups. Unfortunately, when we looked at the effectiveness of melatonin, we found no significant difference in the overall immune response. The seroconversion rates and specific antibody levels remained largely the same between those who took melatonin and those who did not.
However, we did discover something intriguing: individuals taking melatonin had a higher increase in certain immune cell markers. Specifically, there was a notable rise in co-expression of interferon gamma and granzyme B, which play important roles in our immune defense. Although this finding is interesting, the overall impact of melatonin on the flu vaccine response appears limited, warranting further research with larger sample sizes to understand its full potential and any connections to our body’s natural rhythms.
Read More
We explored how melatonin can help address energy exhaustion caused by the Influenza A virus (IAV) in patients suffering from acute exacerbation of chronic obstructive pulmonary disease (AECOPD). In our investigation, we found that individuals with IAV-induced AECOPD showed a significant increase in resting energy expenditure, indicating a heightened metabolic strain.
Our research focused on primary COPD bronchial epithelial cells infected with IAV. We discovered that these cells experienced early and severe energy shortages, with notable damage to their mitochondria—the cell’s powerhouses. Notably, there was a shift from efficient energy production through oxidative phosphorylation (OXPHOS) to less efficient glycolysis, further compounding the issue.
We were pleased to see that melatonin treatment effectively reversed many of these adverse effects. It prompted improvements in mitochondrial function and helped restore ATP levels, which are crucial for energy. By targeting the specific pathways impacted by IAV, such as the OMA1-OPA1-S pathway, melatonin showed considerable promise in improving the clinical outcomes for COPD patients affected by IAV.
These findings suggest that melatonin could be a valuable therapeutic strategy for those suffering from AECOPD triggered by influenza. As we continue to unravel the complexities of viral infections in chronic pulmonary conditions, melatonin may shine as a supportive treatment option.
Read More